Acetyl-boswellic acids (acetyl-BA) are pentacyclic triterpenes derived from the gum resin of frankincense. We have previously shown that these compounds are effective cytotoxic agents, acting through a mechanism that appears to involve the inhibition of topoisomerase activity. We have now investigated the mechanism of action of acetyl-BA and show that these compounds are more potent inhibitors of human topoisomerases I and IIα than camptothecin, and amsacrine or etoposide, respectively. Our data demonstrate that acetyl-BA and, to a lesser extent, some other pentacyclic triterpenes, such as betulinic acid, ursolic acid, and oleanolic acid, inhibit topoisomerases I and IIα through a mechanism that does not involve stabilization of the cleavable complex or the intercalation of DNA. Surface plasmon resonance analysis revealed that topoisomerases I and IIα bind directly to an immobilized derivative of acetyl-BA. This acetyl-BA derivative interacts with human topoisomerases through high-affinity binding sites yielding K D values of 70.6 nM for topoisomerase I and 7.6 nM for topoisomerase IIα. Based on our data, we propose that acetyl-BA inhibit topoisomerases I and IIα through competition with DNA for binding to the enzyme. Thus, acetyl-BA are a unique class of dual catalytic inhibitors of human topoisomerases I and IIα. Topoisomerases are essential enzymes that control and modify the topological state of DNA. These enzymes act by sequential breakage and reunion of either one DNA strand (topoisomerase I) or both DNA strands (topoisomerase II) (Burden and Osheroff, 1998;Pommier et al., 1998). Topoisomerase-mediated strand passing leads to the reduction of DNA twists, as well as the relief of supercoiling, thereby allowing replication, transcription, and recombinant repair to take place (Burden and Osheroff, 1998; Pommier et al., 1998). Numerous studies have shown that rapidly proliferating and transformed cells contain higher levels of topoisomerases (Muller et al., 1985; Burden and Osheroff, 1998), and pharmacological inhibition of these enzymes gained a special interest when it was realized that they are targets of various antitumor and antimicrobial drugs (Burden and Osheroff, 1998;Pommier et al., 1998). Compounds that interfere with topoisomerases are widespread; some of these substances, such as the plant-derived camptothecin and podophyllotoxins have remarkable therapeutic efficacy as antitumor drugs. The mechanisms of interference with topoisomerase activity are quite different and can be divided into two classes: topoisomerase poisons and catalytic inhibitors (Capranico et al., 1997). Poisons stabilize the covalent enzyme-DNA complex and block rejoining of the DNA break. These compounds promote the accumulation of damaged DNA in the cells and, therefore, possess a mutagenic potential (Baguley and Ferguson, 1998) . Catalytic inhibitors of topoisomerases are compounds that prevent binding of enzyme to DNA through interaction either with topoisomerase (Benchokroun et al., 1995; Boege et al., 1996; Frydman et al., 1997; Fortune and Osheroff, 1998) or with DNA (Gatto et al., 1996;Sim et al., 1997; Sorensen et al., 1997). Moreover, substances that interfere with binding or release of ATP during the catalytic cycle of topoisomerase II (Tanabe et al., 1991; Roca et al., 1994) also belong to this class of inhibitors. The gum resin of Boswellia serrata contains boswellic acids (BA) and other pentacyclic triterpenes, which have a chemical structure that closely resembles that of steroids. Recently, we have found that 3-O-acetyl-11-keto-β-BA (AKβBA) as well as the structurally related 3-O-acetyl-β-BA (AβBA) are cytotoxic for the human glioma cell lines U87 MG and U373 MG (Heldt et al., 1997). Subsequent studies performed by us and others have confirmed these results and have shown that BA as well as other pentacyclic triterpenes are effective anticancer agents. Thus, acetyl-BA exhibit cytotoxic effects on human leukemia HL-60 cells (Shao et al., 1998; Hoernlein et al., 1999). Betulinic acid is cytotoxic to human melanoma (Pisha et al., 1995), neurodermal tumors (Fulda et al., 1997), and leukemia L1210 cells (Noda et al., 1997), and ursolic and oleanolic acids inhibit tumor growth in irradiated mice (Hsu et al., 1997). In relation to the mechanism of action of AβBA and AKβBA, we observed that the induced cytotoxicity did not directly correlate with the reported ability of these compounds to inhibit 5-lipoxygenase (Safayhi et al., 1992) but did correlate to morphological changes within the nucleus that are consistent with the inhibition of topoisomerases (Heldt et al., 1997; Hoernlein et al., 1999). Indeed, nuclear extracts from U87 MG and U373 MG glioma cells contain high levels of topoisomerase activity, which is inhibited by the presence of acetyl-BA, strongly suggesting that these compounds are topoisomerase inhibitors (Heldt et al., 1997).
EMSAs were basically performed as described elsewhere (Boege et al., 1996; Osheroff, 1986) . In brief, supercoiled pBR322 DNA was incubated in 20 μl of relaxation topoisomerase I buffer with or without excess of topoisomerase I (100 U) in the presence of the compounds indicated in Fig. 6 (10 μM) at 37°C for 6 min. The reaction was started by addition of DNA. The samples containing two inhibitors were assembled in the order AαBA, topoisomerase, second compound (camptothecin or etoposide). Samples were immediately loaded onto the 1% agarose gel in Tris-acetate-EDTA buffer with 1 μg/ml ethidium bromide and separated by electrophoresis for 6 h at 2 V/cm. Additional control samples containing DNA and enzyme but no test compounds were terminated with SDS and digested with proteinase K to confirm that the DNA shift was caused by enzyme-DNA interaction. EMSA in the presence of topoisomerase IIα (6 U) was performed in 20 μl of topoisomerase II relaxation buffer without ATP essentially as described for the topoisomerase I. Some experiments also were performed in the presence of ATP to define any possible impact of ATP on inhibitory effects of acetyl-BA. DNA electrophoresis was performed in 1% TAE-agarose, pH 6.4. At this pH, topoisomerase IIα is positively charged (pI = 6.5) (Boege et al., 1994), ensuring a stronger shift. Similar results were also obtained when electrophoresis was performed at pH 7 and 8.
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Figure 6
Acetyl-BA prevent binding of topoisomerases to substrate DNA. EMSAs of topoisomerase I (A) and topoisomerase IIα (B) incubated with appropriate DNA are shown. A, topoisomerase I; samples contained pBR322 DNA, 10 μM each inhibitor, and excess of topoisomerase I (100 U) to allow the strongest possible DNA-shift. Control samples were of DNA alone (lane 1) and DNA with topoisomerase I (lane 4). To the samples of lane 2 and 3 DNA was added together with AαBA or AKβBA (10 μM) to show that acetyl-BA had no influence on the pBR322 mobility (similar results were obtained with pRYG DNA; data not shown). AαBA was added to the sample in lane 8 before camptothecin. The reactions were started with the addition of DNA and incubated for 6 min at 37°C. Samples were separated on 1% TAE-agarose gel electrophoresis in the presence of ethidium bromide for 6 h. Under these conditions supercoiled and relaxed free DNA had similar mobility, and protein-bound DNA migrated more slowly. The control sample containing DNA and topoisomerase I (lane 9) was terminated with SDS, and topoisomerase was digested with proteinase K. The resulting nonbound, relaxed DNA migrates in ethidium bromide gel slightly faster than supercoiled DNA. B, topoisomerase IIα; assays were performed with pRYG DNA and 10 U of enzyme in 20 μl of assay buffer in the presence of Mg 2+ ions, but without ATP. The reaction was carried out as described above for topoisomerase I. Binding of topoisomerase IIα to DNA in the presence of etoposide (lane 5) was used as a positive control. AαBA was added to sample 6 before etoposide. Denaturation of topoisomerase IIα with SDS and subsequent digestion with proteinase K released the protein-bound DNA (lane 7). One of three representative experiments is shown.
Measurement of DNA Intercalation.
Intercalation was determined by the unwinding assay (Pommier et al., 1985) . Supercoiled pBR322 DNA was relaxed with 300 U of topoisomerase I at 37°C for 15 min in topoisomerase I relaxation buffer. To confirm full relaxation of DNA, one sample (lane 2) was terminated with SDS after 15 min. Inhibitors were added (20 μM each acetyl-BA or the intercalator amsacrine) and the incubations were continued for another 60 min. Parallel experiments ensured that topoisomerase I retained its activity in the presence of the compounds used. The reaction was terminated by addition of 1% (w/v) SDS and followed by digestion with proteinase K as described above. The compounds were removed by extraction with chloroform/isoamyl alcohol (24:1). For a better resolution of topoisomers, DNA was separated on 1% agarose Tris-phosphate-EDTA buffer (36 mM Tris·HCl, pH 7.8, 1 mM EDTA, and 30 mM NaH2PO4) gel with 0.2 μg/ml chloroquine for 15 h at 0.4 V/cm. After removal of chloroquine, the gel was stained with ethidium bromide and photographed as described above. Surface Plasmon Resonance Analysis of Acetyl-BA-Topoisomerase Interaction. Measurements were performed on the IBIS optical sensor device (XanTec Analysensysteme, Muenster, Germany). The instrument uses surface plasmon resonance (SPR) to measure changes in the refractive index of p-polarized light (670 nm) close to the sensor surface. These changes in refractive index are related to the amount of macromolecules bound to the sensor surface. The signal is recorded in millidegrees. A response of 120 m° represents a change in surface protein of approximately 1 ng/mm 2 . AαBA, used for immobilization onto a SPR sensor chip, was deacetylated and coupled to 6-aminocaproic acid anhydride. The product, 3-O-(6-aminocaproyl)-α-BA, reacted with (+)-biotin-Nhydroxysuccinimidyl ester to yield the conjugate 3-O-(N-(+)-biotinyl-6-aminocaproyl)-α-boswellic acid (biotinyl-AC-αBA). The conjugate was subsequently bound to neutravidin and the resulting complex immobilized on the sensor surface according to standard procedures. For the SPR analysis of topoisomerase binding, a planar carboxylated sensor chip covered with a maleic acid-ethylene copolymer (XanTec Analysensysteme, Muenster, Germany) was used. Immobilization was carried on to a density equivalent to a sensor response of 490 ± 23 m°. Both topoisomerase I (Lot no. MR159) and topoisomerase IIα (Lot no. AP159) were thawed on ice and transferred by gel filtration into corresponding relaxation buffers before each experiment. Measurements were performed with the indicated concentrations of topoisomerases at 20°C in 50 μl of relaxation buffer. Topoisomerase IIα measurements were performed in absence of ATP. The increase of the response after injection of enzyme reflects binding to the immobilized ligand. After recording of the association, the liquid phase was replaced by assay buffer and dissociation was monitored for another 200 to 300 s. Binding of plasmid DNA (pBR322 or pRYG, 30 μg/ml) to surface-bound biotinyl-AC-αBA was measured by application of 50 μl of each DNA solution over the sensor surface. After each measurement, the sensor chip was regenerated with 1 M NaCl in 0.1 M NaOH. There were no mass transport limitations during the measurements as confirmed by the analysis with the software supplied with the instrument. Analysis of the data was performed with the IBIS kinetic evaluation program. Using SPR biosensors, the kinetic parameters of a single-phase association can be determined by nonlinear regression of the data points as the most robust data analysis (O'Shannessy et al. 1993) by the equation:
where R is the SPR response,R 0 is response at the t = 0, C is the concentration of the analyte in M,k a is the association rate constant in M −1 s −1 , andk d is the dissociation rate constant in s −1 (O'Shannessy et al., 1993). The model allows determination of rate constants without reaching equilibrium during the experimental cycle. The relevant kinetic information was obtained from the parameter k s = (k aC + k d). A plot of k s values versus concentration is used for linear regression to obtain the association rate constant from the slope and the dissociation rate constant from they-intercept. Data from the entire association phase were used to determine the kinetic constants. Dissociation rate constants calculated from the dissociation phase yielded comparable results.
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Results
Acetyl-BA Inhibit the Catalytic Activity of Topoisomerases I and IIα. The gum resin of Boswellia serrata contains both acetylated and nonacetylated forms of BA. Figure1 shows the chemical structures of three of the acetylated forms of these compounds: acetyl-α-boswellic acid (AαBA), AβBA, and AKβBA. All three acetyl-BA inhibited human topoisomerases I and IIα in a concentration-dependent manner in DNA relaxation assays ( Fig. 2A and B) . In addition, equivalent inhibitory effects on topoisomerase IIα were demonstrated in decatenation assays, where the catalytic activity of topoisomerase IIα results in decatenated kinetoplast DNA yielding open circular DNA (Fig. 2C , upper band) and closed circular DNA (Fig.2C , lower band) able to penetrate into the gel (Fig. 2C) . A comparison of the relative efficacies of the three acetyl-BA showed that AαBA > AβBA > AKβBA (Fig.2, A-C) . The IC50 value for the inhibition of the catalytic activity of topoisomerases I and IIα by AαBA was ∼3 μM (n = 5) and ∼1 μM (relaxation, n = 9; decatenation, n= 4), respectively. Moreover, under these experimental conditions AαBA seemed to be more potent than camptothecin, amsacrine, or etoposide in inhibiting the activity of topoisomerases I or IIα. To exclude nonspecific interactions with DNA-processing enzymes, we determined the effects of acetyl-BA, such as AαBA, AβBA, and AKβBA on the catalytic activity of bovine DNase I. In contrast to topoisomerases, acetyl-BA (10-100 μM) did not impair the activity of DNase I (0.4-4.0 U/ml; data not shown).
We next compared AαBA with the structurally related pentacyclic triterpenes shown in Fig. 3 for topoisomerase inhibition. Whereas AαBA effectively inhibited DNA relaxation by both topoisomerases I and IIα, neither amyrin isoform nor 18-β-glycyrrhetinic acid had significant effects in the concentrations used (Fig. 4) . Similar to acetyl-BA, the other pentacyclic triterpenes tested inhibited both topoisomerases. The most effective of these compounds was betulinic acid having an IC50 value of ∼43 μM and ∼5 μM for topoisomerases I and IIα, respectively (Fig.4) . Considering the structural features of the various pentacyclic triterpenes used in this study, the above results suggest that the shared pentacyclic ring conformation is important but not sufficient for the inhibition of topoisomerases. Moreover, our results also suggest that the combination of the carboxyl group at the fourth carbon (ring A) and the α position of the two methyl groups at ring E is important for enhancing the inhibitory activity of the molecule toward both topoisomerases: AαBA possesses the highest inhibitory efficacy. Similar results were obtained in experiments with topoisomerase IIα (Fig. 5B) . Etoposide blocks topoisomerase IIα-mediated DNA religation, which could be monitored by the appearance of linear DNA. Neither AαBA nor AKβBA (1 and 100 μM) increased the level of DNA scission, but both of them prevented formation of cleavable complex in the presence of etoposide. Experiments performed with AβBA and betulinic and oleanolic acids (100 μM) demonstrated no stabilization of enzyme-DNA cleavable complexes, indicating the same mechanism of action for different pentacyclic triterpenes (data not shown). Taken together, the above experiments demonstrate that acetyl-BA are not topoisomerase poisons. Acetyl-BA Prevent Binding of Topoisomerases I and IIα to the Substrate DNA. We next investigated whether acetyl-BA directly interfere with binding of topoisomerase I (Fig.6A) or IIα (Fig. 6B) to DNA using an EMSA. Excess topoisomerase was used in either case to ensure a stronger shift. Acetyl-BA alone did not interfere with the electrophoretic mobility of plasmid DNA. Both topoisomerases formed complexes with plasmid DNA, and treatment of these complexes with SDS and proteinase K released the DNA. Figure 6 also demonstrates that acetyl-BA inhibited the formation of these enzyme-DNA complexes. AKβBA was less effective than AαBA in respect to topoisomerase IIα inhibition in accordance with the data from the DNA relaxation assays above. AαBA and AKβBA inhibited the binding of DNA by topoisomerase IIα in both the presence (data not shown) and absence of ATP (Fig. 6B) . The topoisomerase IIα-DNA complex was relatively immobile and was retained close to the application slot (Fig. 6B,  lane 2) . Similar to AαBA and AKβBA, AβBA, betulinic acid, and oleanolic acid also inhibited topoisomerase-DNA complex formation (data not shown). In contrast, DNA binding of topoisomerase I was not affected by camptothecin (Fig. 6A, lane 7) nor was that of topoisomerase IIα affected by etoposide (Fig. 6B, lane 5) . These observations are consistent with the mechanism of action of these compounds, both camptothecin and etoposide do not interfere with the binding and scission steps of either topoisomerase. When added before camptothecin and etoposide, AαBA prevents binding of either topoisomerase to DNA, suggesting that it inhibits the formation of tertiary complexes between enzyme, topoisomerase poison (camptothecin or etoposide), and DNA, further supporting the notion that acetyl-BA inhibit the DNA-binding step of both topoisomerases. Acetyl-BA Do Not Intercalate into DNA. To elucidate further the mechanism of topoisomerase inhibition, we investigated the DNA binding characteristics of acetyl-BA. We employed a DNA unwinding assay to assess any possible impact of acetyl-BA on the superhelical state of closed circular DNA. This assay is based on the ability of intercalating compounds to unwind the DNA duplex and thereby change the DNA twist (Waring, 1981) . These drug-induced changes in DNA twist also induce structural tension in the DNA backbone; this tension can be relieved by topoisomerases. On removal of both topoisomerase and intercalating agent, the unwinding effect of the intercalating compound is no longer present and the DNA returns to a supercoiled state. Figure7 shows that the classical intercalator amsacrine affected the gaussian distribution of the DNA topoisomers by shifting them down (i.e., into the supercoiled state); however, neither AαBA nor AKβBA had any effect, suggesting that the mechanism through which acetyl-BA inhibit topoisomerases was independent of DNA intercalation. Similar results were obtained using AβBA, betulinic acid, and oleanolic acid (data not shown). Furthermore, acetyl-BA did not impair staining of DNA by ethidium bromide (not shown), which is known to bind through the minor grove. Thus, acetyl-BA interfere with human topoisomerases through a mechanism different from that of agents that either intercalate DNA or bind to the minor grove of DNA. To determine whether this mechanism involved direct binding of acetyl-BA to topoisomerases, we performed binding experiments using SPR. Acetyl-BA do not intercalate into DNA. Interaction of acetyl-boswellic acids with DNA was measured in an unwinding assay. Negatively supercoiled pBR322 DNA was relaxed in the presence of excess of topoisomerase I (300 U) for 15 min. Test compounds were added after 15 min of full relaxation and incubated for another 60 min. The negative control contained DNA alone (lane 1). Full DNA relaxation induced by topoisomerase I after 15 min and 75 min is shown in lanes 2 and 3, respectively. Lanes 4 to 6 show the effects of the indicated compounds at the concentration of 20 μM on the helical state of relaxed DNA. The intercalator amsacrine was used as a positive control (lane 6). The compounds were removed with organic solvent. For better separation of the DNA topoisomers, the electrophoresis was carried out in the presence of chloroquine for 12 h. One of three experiments is shown.
Binding of an Acetyl-BA Derivative to Topoisomerases I and IIα as Measured by SPR.
We immobilized a derivative of AαBA to the surface of the plasmon resonance sensor chip by creating a biotinyl-AC-αBA (Fig. 8A) . This compound added to the fluid phase of the relaxation assays was fully active in inhibiting topoisomerase activity, showing an IC50 value of ∼12 μM and ∼2 μM for the inhibition of topoisomerases I and IIα, respectively (Fig. 8, B and C). 9 shows the binding curves of topoisomerases I and IIα to biotinyl-AC-αBA linked to the sensor chip surface. There was no unspecific binding of topoisomerases to the sensor surface after the activated carboxymethyl groups had been blocked with ethanolamine (data not shown). Furthermore, once bound, there was no detectable dissociation of the immobilized BA from the sensor surface even after many cycles of binding and regeneration. The binding of topoisomerase I to biotinyl-AC-αBA was concentration-dependent ( Fig. 9A) and followed a one-phase reaction. The apparent rate constants for the single class high affinity binding sites were determined as: k a = 9.1 × 10 4 M −1 s −1 andk d = 6.5 × 10 −3 s −1 . The apparent equilibrium dissociation constant (K D) was calculated as 70.6 nM. The kinetics of topoisomerase I binding to biotinyl-AC-αBA were slower than that for topoisomerase IIα (Fig.9B) , and removal of the nonbound topoisomerase I resulted in a similarly slow dissociation of the complex. In some experiments, topoisomerase I was mixed with either biotinyl-AC-αBA (40 μM) or pBR322 DNA (30 μg/ml) and then applied to the sensor surface. In those experiments, no binding to the immobilized ligand could be detected (data not shown), demonstrating the specificity of the reaction. In accordance with the unwinding assay, binding of pBR322 and pRYG plasmid DNA to biotinyl-AC-αBA was undetectable (data not shown). 
Discussion
In this article, we show that acetyl-BA inhibit human topoisomerases I and IIα. We further describe the molecular mechanism of this inhibition, demonstrating that acetyl-BA inhibit topoisomerase action by directly binding to the enzyme, not by binding to DNA or by complex formation with enzyme and DNA. Our data suggest that acetyl-BA inhibit both topoisomerases I and IIα using the same mechanism; that is, by competing with DNA for topoisomerase binding. This inhibition seems to be specific, because acetyl-BA did not affect the activity of bovine DNase I. Thus, we propose acetyl-BA as a new class of topoisomerase inhibitors.
Pentacyclic triterpenes are widespread in nature and are a part of our daily diet as constituents of fruits and vegetables. Some pentacyclic triterpenes are known to possess antitumor activity, but the mechanism through which these compounds achieve this effect has not been elucidated (Pisha et al., 1995; Fulda et al., 1997;Heldt et al., 1997). Boswellic acids belong to the class of pentacyclic triterpenes, and we have recently described the acetyl-BA, AKβBA, to induce cell cytotoxicity through a mechanism involving the inhibition of topoisomerase I (Hoernlein et al., 1999). We isolated and characterized several different BA and found that not only did these compounds inhibit topoisomerase I, but also topoisomerase IIα activity. Analysis of the structure-activity relationship suggested that the general pentacyclic ring structure of the BA was important for topoisomerase inhibitory activity but was in itself not sufficient because β-amyrin was inactive and α-amyrin had only a negligible effect on topoisomerases IIα. AαBA and AβBA differ from α and β-amyrin in that they are acetylated and carboxylated on positions 3 and 4 of ring A, respectively. This indicates that the nature and arrangement of the side groups is important. Our study suggests that carboxylation of the pentacyclic ring structure, and particularly on rings A and D, is necessary for topoisomerase inhibition. We found that those compounds that contain a carboxyl group (betulinic acid, ursolic acid, oleanolic acid, and acetyl-BA) all inhibit topoisomerases, although β-amyrin was not active. That 18-β-glycyrrhetinic acid was not an effective topoisomerase inhibitor could be attributed to either the carboxylation on ring E or to the keto group at position 11 on ring C. Because AKβBA also contains this keto group and is the least effective of the acetyl-BA, it is possible that this position of the pentacyclic triterpenes is important for enzyme inhibition. Considering the structural differences between the compounds tested in connection with their relative efficacy, we would propose that pentacyclic triterpenes could serve as backbones for the rational design of specific topoisomerase inhibitors. Inhibition of human topoisomerases by acetyl-BA seems to be specific, because they did not impair the activity of DNase I. DNase I-related enzymes, which are members of the family of Ca 2+ -and Mg 2+ -dependent endonucleases, have recently been implicated in DNA fragmentation during apoptosis (Mannherz et al. 1995) . Thus, the lack of inhibition of DNase I by acetyl-BA is consistent with our earlier observation that acetyl-BA induce DNA fragmentation and apoptosis in HL-60 and CCRF-CEM cells (Hoernlein et al., 1999) . Our observation that acetyl-BA inhibit topoisomerases I and IIα suggests that these compounds may have a mechanism of action that is similar to those of other dual topoisomerase inhibitors. In general, such inhibitors interact directly with DNA and include agents that intercalate DNA, or bind into the minor groove (Pilch et al., 1997;Pommier et al., 1998; Xu et al., 1998). For example, topoisomerase IIα inhibition is strongly correlated with the ability of a compound to intercalate DNA, whereas drug binding to the minor groove is essential for the inhibition of topoisomerase I (Pilch et al., 1997; Xu et al., 1998). In either case, such substances stabilize the enzyme-DNA cleavable complex and interfere with the scissionreligation step; hence, these compounds are referred to as topoisomerase poisons. In this respect, topoisomerase poisons may induce DNA breakage in addition to their topoisomerase inhibitory function, leading to the significant toxicities associated with these compounds (Baguley and Ferguson, 1998) . Our data show that acetyl-BA neither directly bind to DNA nor promote DNA breakage. Thus, this observation places acetyl-BA apart from other dual topoisomerase inhibitors and explains the low toxicity and the low incidence of side effects associated with the use of phytopharmacological drugs containing these compounds (Gupta et al., 1998) .
We propose that the mechanism through which acetyl-BA impair topoisomerase function is by direct binding through a single class of high-affinity binding sites to each enzyme. Indeed, acetyl-BA inhibit the enzyme-DNA complex formation as shown by EMSA, and directly bind to topoisomerases I and IIα as demonstrated by SPR, a reaction that was inhibited if the enzymes were preincubated with DNA. Thus, our data suggest that acetyl-BA might compete with DNA for the same binding sites on topoisomerases, thereby acting as catalytic inhibitors.
Compared with topoisomerase IIα, the interaction of immobilized biotinyl-AC-αBA with topoisomerase I followed slower association and dissociation kinetics, giving a 9-fold higher value forK D. A similar difference was observed in the topoisomerase relaxation assays with biotinyl-AC-αBA. The other three acetyl-BA tested also inhibited topoisomerase IIα more effectively than topoisomerase I, which indicates that the inhibitory effect of acetyl-BA on human topoisomerases correlates with the binding characteristics to either enzyme. Our observation that acetyl-BA inhibit both human topoisomerases is surprising because it seems to suggest similar structural or functional domains. However, although topoisomerases I and IIα have similar functions, these enzymes are completely different. On the other hand, some poisons such as actinomycin D, intoplicine, nitidine, and others act against both topoisomerases (Withoff et al., 1996; Pommier et al., 1998) suggesting some structural characteristics that might be shared by both enzymes. As far as the effects of acetyl-BA on human topoisomerase I and IIα are concerned, the common mechanistic features are obviously related to the first steps of the catalytic cycle: DNA binding and/or conformational changes, either of which might be affected by acetyl-BA. Interestingly, recent studies of the crystal structure of human topoisomerase I revealed the existence of three β strands that are analogous to a three-stranded antiparallel β-sheet structure from yeast topoisomerase II. These structures located in close proximity to the DNA cleavage sites harbor putative DNA-binding domains and are believed to represent a common DNA-binding motif among DNA topoisomerases (Berger et al., 1998; Redinbo et al., 1999) . They might therefore accommodate targets for acetyl-BA binding. In this context it is intriguing that the inhibitory activity of pentacyclic triterpenes is critically dependent on the carboxylic group carrying an electronegative potential. By the same token, it is known that a relatively large number of electropositively charged amino groups of topoisomerase I form protein-phosphate interactions with the base pairs adjacent to the DNA cleavage site (Redinbo et al., 1999) . Further studies will have to clarify whether acetyl-BA can intercept any of those protein-phosphate interactions. Moreover, at present it cannot be excluded that on the basis of their electronegative potential acetyl-BA might interact with some site of the likewise positively charged A′ domain groove, the putative primary DNA binding region of topoisomerase II (Berger et al., 1998). Future studies with appropriate topoisomerase mutants and/or photocrosslinking should provide further insights into the site-directed molecular mechanism of acetyl-BA. In addition, such experiments are expected to help us better understand the specific features of topoisomerase-DNA interactions. , 1997) . Our data suggest that the previously observed cytotoxic effects of acetyl-BA and other pentacyclic triterpenes might be a result of their ability to inhibit the activity of human topoisomerases, particularly topoisomerase IIα, which is known to be essential for the survival of eukaryotic cells (Andoh and Ishida, 1998; Burden and Osheroff, 1998) . Poisons of topoisomerases I and IIα, such as camptothecin or etoposide, trap enzyme-DNA cleavable complexes, leading to DNA strand breaks and, by mechanisms not yet completely defined, finally to cell death. Even less is known about the mechanisms and events that link the inhibition of the catalytic activity of topoisomerases to cell death (Andoh and Ishida, 1998; Burden and Osheroff, 1998; Pommier et al., 1998) . It has been shown that catalytic inhibitors of topoisomerase II, such as the bisdioxopiperazines ICRF-187 and ICRF-193, result in a failure of dividing cells to accomplish normal mitosis. This is caused by incomplete chromosome condensation and segregation leading to polyploidization and, finally, to cell death (Roca et al. 1994; Andoh and Ishida, 1998). The cytotoxicity of ICRF-187 seems to correlate with the inhibition of the catalytic activity of topoisomerase II. In addition, recent evidence indicates that accumulation of closed clamp formations trapped on DNA might interfere with transcription, or other metabolic processes, resulting in cell death (Andoh and Ishida, 1998; Jensen et al., 2000) . The signaling and execution events by which acetyl-BA trigger apoptosis and cytotoxicity are currently the subject of intense investigations. The ability of acetyl-BA to inhibit both topoisomerases simultaneously might result in an enhanced antitumor efficacy, specifically because topoisomerase I, unlike topoisomerase II, is a cell-cycle-independent enzyme (Burden and Osheroff, 1998; Hande, 1998; Pommier et al., 1998) . Acting on different cellular targets, these compounds may possibly have advantages similar to clinical combination therapy. Indeed, preliminary data suggest that acetyl-BA might be more potent cytotoxic agents for glioma cell lines than the poisons camptothecin and etoposide (our unpublished data). It is intriguing that acetyl-BA are lipophilic; they might therefore penetrate the blood-brain barrier, making these compounds promising therapeutic agents for the treatment of malignant brain tumors. Clinical studies are now underway to assess the value of acetyl-BAs for the treatment of human astrocytomas and glioblastomas. Previous SectionNext Section 
